title: [Newly developed H2-receptor antagonists in the treatment of peptic ulcer disease].
abstract: Ranitidine and oxmetidine are newly developed histamine H2-receptor antagonists without any antiandrogenic activity and probably without drug interactions. In numerous clinical trials ranitidine has been proven to be at least as effective as cimetidine in the short- and long-term treatment of peptic ulcer disease. Ranitidine was found to be remarkably safe. Its therapeutic use in man should not be associated with significant adverse reactions.
mesh_terms: D001682:Biological Availability; D004381:Duodenal Ulcer / Q000188:drug therapy; D005663:Furans / Q000627:therapeutic use*; D006635:Histamine H2 Antagonists / Q000627:therapeutic use*; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use; D010437:Peptic Ulcer / Q000188:drug therapy*; D011899:Ranitidine
chemical_list: D005663:Furans; D006635:Histamine H2 Antagonists; D007093:Imidazoles; D011899:Ranitidine; C027703:oxmetidine
vernacular_title: Therapie der peptischen Ulkuserkrankung mit neu entwickelten H2-Rezeptor-Antagonisten.